Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Other Working Capital Changes (2022 - 2025)

Historic Other Working Capital Changes for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$419000.0.

  • Entrada Therapeutics' Other Working Capital Changes rose 9753.05% to -$419000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.4 million, marking a year-over-year increase of 4915.53%. This contributed to the annual value of -$119.8 million for FY2024, which is 18559.25% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Other Working Capital Changes stood at -$419000.0, which was up 9753.05% from -$770000.0 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Other Working Capital Changes ranged from a high of $211.6 million in Q1 2023 and a low of -$87.0 million during Q2 2024
  • In the last 4 years, Entrada Therapeutics' Other Working Capital Changes had a median value of -$5.1 million in 2022 and averaged $965733.3.
  • Data for Entrada Therapeutics' Other Working Capital Changes shows a peak YoY increase of 1256958.08% (in 2023) and a maximum YoY decrease of 104755.24% (in 2023) over the last 5 years.
  • Over the past 4 years, Entrada Therapeutics' Other Working Capital Changes (Quarter) stood at $2.0 million in 2022, then tumbled by 1047.55% to -$19.0 million in 2023, then plummeted by 77.73% to -$33.7 million in 2024, then soared by 98.76% to -$419000.0 in 2025.
  • Its Other Working Capital Changes was -$419000.0 in Q3 2025, compared to -$770000.0 in Q2 2025 and -$18.5 million in Q1 2025.